[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgmBTO2ZMzqbMqmrlYWi2D5MetQZQbiHDomm8PQcH1bg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":75,"rows":82},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)",[4],102,false,17,3,66668,9,41,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Alcoholism",39,{"name":18,"count":19},"Alcohol Dependence",19,{"name":21,"count":22},"Alcohol Use Disorder",14,{"name":24,"count":25},"Alcohol Drinking",12,{"name":27,"count":28},"Alcohol-Related Disorders",7,{"name":30,"count":28},"Healthy",{"name":32,"count":33},"Normal Physiology",6,{"name":35,"count":36},"Alcohol Abuse",5,[38,43,48,52,56,61,66,71],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07046819","Tirzepatide in MetALD","2026-07-30","Tirzepatide",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04781322","Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers","2026-12-31","Alirocumab",{"nctId":49,"briefTitle":50,"date":46,"intervention":51},"NCT03294460","Nicotinic Receptor Genetic Variation and Alcohol Reward","Alcohol",{"nctId":53,"briefTitle":54,"date":46,"intervention":55},"NCT06269627","Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder","Acamprosate calcium",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07325266","Human Laboratory Study of Apremilast for Alcohol Use Disorder","2027-01-31","Apremilast",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06819189","Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors","2027-12-31","Ethanol",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06484075","Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms","2028-12-31","Suvorexant",{"nctId":72,"briefTitle":73,"date":74,"intervention":42},"NCT07559500","Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)","2031-12-31",[76,77,78,79,80,81],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[83,106,137,159,181,225,265,294,316,337,427,469,498,522,540,564,597,615,633,651,669,687,705,723,741,759,791,813,848,873,907,931,959,977,995,1013,1038,1062,1087,1112,1138,1156,1180,1203,1227,1250,1273,1300,1325,1343,1366,1393,1411,1435,1459,1484,1508,1533,1551,1578,1596,1614,1632,1650,1674,1697,1721],{"intervention":55,"totalTrials":84,"cells":85},1,{"EARLY_PHASE1":86,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":95,"NA":104},{"trials":87,"activeCount":88},[],0,{"trials":90,"activeCount":88},[],{"trials":92,"activeCount":88},[],{"trials":94,"activeCount":88},[],{"trials":96,"activeCount":84,"soonestReadout":46},[97],{"nctId":53,"briefTitle":54,"status":98,"phases":99,"primaryCompletion":46,"completion":46,"start":100,"enrollment":101,"conditions":102,"interventions":103},"RECRUITING",[80],"2025-05-07",48,[21],[55],{"trials":105,"activeCount":88},[],{"intervention":42,"totalTrials":107,"cells":108},2,{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":122,"PHASE3":131,"PHASE4":133,"NA":135},{"trials":110,"activeCount":88},[],{"trials":112,"activeCount":84,"soonestReadout":74},[113],{"nctId":72,"briefTitle":73,"status":98,"phases":114,"primaryCompletion":74,"completion":74,"start":115,"enrollment":116,"conditions":117,"interventions":119},[77],"2026-05-20",176,[118],"Alcohol Use Disorder (AUD)",[42,120,121],"[11C]raclopride plus drug","[11C]NNC-112",{"trials":123,"activeCount":84,"soonestReadout":41},[124],{"nctId":39,"briefTitle":40,"status":98,"phases":125,"primaryCompletion":41,"completion":41,"start":126,"enrollment":127,"conditions":128,"interventions":130},[78],"2026-04-01",120,[129,21],"Metabolic Alcohol-associated Liver Disease",[42],{"trials":132,"activeCount":88},[],{"trials":134,"activeCount":88},[],{"trials":136,"activeCount":88},[],{"intervention":60,"totalTrials":84,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":153,"PHASE4":155,"NA":157},{"trials":140,"activeCount":88},[],{"trials":142,"activeCount":88},[],{"trials":144,"activeCount":84,"soonestReadout":59},[145],{"nctId":57,"briefTitle":58,"status":98,"phases":146,"primaryCompletion":59,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":152},[78],"2027-07-31","2026-04-03",100,[21,151],"Alcohol Misuse",[60],{"trials":154,"activeCount":88},[],{"trials":156,"activeCount":88},[],{"trials":158,"activeCount":88},[],{"intervention":70,"totalTrials":84,"cells":160},{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":162,"activeCount":88},[],{"trials":164,"activeCount":88},[],{"trials":166,"activeCount":84,"soonestReadout":69},[167],{"nctId":67,"briefTitle":68,"status":98,"phases":168,"primaryCompletion":69,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":174},[77,78],"2029-12-31","2024-11-21",180,[173,118],"Healthy Volunteers",[70],{"trials":176,"activeCount":88},[],{"trials":178,"activeCount":88},[],{"trials":180,"activeCount":88},[],{"intervention":65,"totalTrials":9,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":205,"PHASE3":219,"PHASE4":221,"NA":223},{"trials":184,"activeCount":88},[],{"trials":186,"activeCount":84,"soonestReadout":64},[187,198],{"nctId":188,"briefTitle":189,"status":190,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT01375556","Genetics of the Acute Response to Alcohol in Social Drinkers","TERMINATED",[77],"2016-01-20","2011-05-26",33,[15,196],"Genetics",[65],{"nctId":62,"briefTitle":63,"status":98,"phases":199,"primaryCompletion":64,"completion":64,"start":200,"enrollment":201,"conditions":202,"interventions":204},[77],"2025-06-10",50,[203],"Healthy Volunteer",[65],{"trials":206,"activeCount":88},[207],{"nctId":208,"briefTitle":209,"status":210,"phases":211,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":218},"NCT00247585","Hangover, Congeners, Sleep and Occupational Performance","COMPLETED",[78],"2006-06","2003-09",140,[216,217],"Sleep","Neurobehavioral Manifestations",[65],{"trials":220,"activeCount":88},[],{"trials":222,"activeCount":88},[],{"trials":224,"activeCount":88},[],{"intervention":51,"totalTrials":9,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":247,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":228,"activeCount":88},[],{"trials":230,"activeCount":84,"soonestReadout":46},[231,241],{"nctId":232,"briefTitle":233,"status":210,"phases":234,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT00713492","Computer-Assisted Self-Administration of Ethanol",[77],"2023-12-11","2008-10-29",229,[239],"Alcoholic Intoxication",[51],{"nctId":49,"briefTitle":50,"status":98,"phases":242,"primaryCompletion":46,"completion":46,"start":243,"enrollment":244,"conditions":245,"interventions":246},[77],"2019-06-10",128,[24],[51,51,51],{"trials":248,"activeCount":88},[249],{"nctId":250,"briefTitle":251,"status":210,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":8,"conditions":255,"interventions":257},"NCT01779024","Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers",[78],"2017-06-01","2012-12-13",[256,24,15],"fMRI",[258,51],"Ghrelin",{"trials":260,"activeCount":88},[],{"trials":262,"activeCount":88},[],{"trials":264,"activeCount":88},[],{"intervention":120,"totalTrials":107,"cells":266},{"EARLY_PHASE1":267,"PHASE1":280,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":292},{"trials":268,"activeCount":88},[269],{"nctId":270,"briefTitle":271,"status":210,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT03190954","Brain Dopaminergic Signaling in Opioid Use Disorders",[76],"2025-10-27","2017-08-17",153,[32,277],"Opioid Use Disorders",[279,120,121],"[11C]raclopride plus placebo",{"trials":281,"activeCount":84,"soonestReadout":74},[282],{"nctId":72,"briefTitle":73,"status":98,"phases":283,"primaryCompletion":74,"completion":74,"start":115,"enrollment":116,"conditions":284,"interventions":285},[77],[118],[42,120,121],{"trials":287,"activeCount":88},[],{"trials":289,"activeCount":88},[],{"trials":291,"activeCount":88},[],{"trials":293,"activeCount":88},[],{"intervention":121,"totalTrials":107,"cells":295},{"EARLY_PHASE1":296,"PHASE1":302,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":297,"activeCount":88},[298],{"nctId":270,"briefTitle":271,"status":210,"phases":299,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":300,"interventions":301},[76],[32,277],[279,120,121],{"trials":303,"activeCount":84,"soonestReadout":74},[304],{"nctId":72,"briefTitle":73,"status":98,"phases":305,"primaryCompletion":74,"completion":74,"start":115,"enrollment":116,"conditions":306,"interventions":307},[77],[118],[42,120,121],{"trials":309,"activeCount":88},[],{"trials":311,"activeCount":88},[],{"trials":313,"activeCount":88},[],{"trials":315,"activeCount":88},[],{"intervention":47,"totalTrials":84,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":319,"activeCount":88},[],{"trials":321,"activeCount":84,"soonestReadout":46},[322],{"nctId":44,"briefTitle":45,"status":98,"phases":323,"primaryCompletion":46,"completion":46,"start":324,"enrollment":149,"conditions":325,"interventions":328},[77],"2021-10-19",[326,327],"Alcohol Associated Liver Disease","Heavy Drinking Behavior",[47],{"trials":330,"activeCount":88},[],{"trials":332,"activeCount":88},[],{"trials":334,"activeCount":88},[],{"trials":336,"activeCount":88},[],{"intervention":338,"totalTrials":339,"cells":340},"naltrexone",8,{"EARLY_PHASE1":341,"PHASE1":354,"PHASE2":356,"PHASE3":377,"PHASE4":390,"NA":425},{"trials":342,"activeCount":88},[343],{"nctId":344,"briefTitle":345,"status":210,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT00667771","The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion",[76],"2010-12-27","2011-04-04","2008-04-22",70,[18,15],[353],"Naltrexone",{"trials":355,"activeCount":88},[],{"trials":357,"activeCount":88},[358,367],{"nctId":359,"briefTitle":360,"status":210,"phases":361,"completion":362,"enrollment":363,"conditions":364,"interventions":365},"NCT00000440","Sertraline and Naltrexone for Alcohol Dependence",[78],"2002-09",124,[15],[338,366],"sertraline",{"nctId":368,"briefTitle":369,"status":210,"phases":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":375},"NCT00027079","Combined Pharmacotherapies for Alcoholism (Naltrexone\u002FOndansetron)",[78],"2004-08","2001-09",360,[15],[376,338],"ondansetron",{"trials":378,"activeCount":88},[379],{"nctId":380,"briefTitle":381,"status":210,"phases":382,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":389},"NCT00444418","Medication and Counseling for Controlled Drinking (Project SMART)",[79],"2010-02","2010-06","2006-04",200,[388,24,15,35],"Alcohol-related Disorders",[353],{"trials":391,"activeCount":88},[392,400,411,418],{"nctId":393,"briefTitle":394,"status":210,"phases":395,"completion":396,"enrollment":397,"conditions":398,"interventions":399},"NCT00000452","Naltrexone Treatment of Alcohol Dependence",[80],"2003-01",240,[15],[338],{"nctId":401,"briefTitle":402,"status":210,"phases":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":409},"NCT00006204","Drug Treatment for Depressed Alcoholics (Naltrexone\u002FFluoxetine)",[80],"2006-01","2000-03",106,[15,18,408],"Depression",[338,410],"fluoxetine",{"nctId":412,"briefTitle":413,"status":210,"phases":414,"completion":405,"enrollment":415,"conditions":416,"interventions":417},"NCT00000449","Behavior and Naltrexone Treatment for Alcoholics",[80],160,[15],[338],{"nctId":419,"briefTitle":420,"status":210,"phases":421,"completion":362,"enrollment":422,"conditions":423,"interventions":424},"NCT00000445","Use of Naltrexone in a Clinical Setting",[80],300,[15],[338],{"trials":426,"activeCount":88},[],{"intervention":428,"totalTrials":9,"cells":429},"lorazepam",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":455,"PHASE4":457,"NA":467},{"trials":431,"activeCount":88},[],{"trials":433,"activeCount":88},[],{"trials":435,"activeCount":88},[436,447],{"nctId":437,"briefTitle":438,"status":210,"phases":439,"completion":440,"start":441,"enrollment":415,"conditions":442,"interventions":444},"NCT00229125","Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam",[78],"2005-09","2001-07",[443],"Alcohol Withdrawal Syndrome(AWS)",[445,446],"Gabapentin","Lorazepam",{"nctId":448,"briefTitle":449,"status":210,"phases":450,"completion":451,"enrollment":415,"conditions":452,"interventions":453},"NCT00011297","Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal",[78],"2005-12",[15],[454,428],"gabapentin",{"trials":456,"activeCount":88},[],{"trials":458,"activeCount":88},[459],{"nctId":460,"briefTitle":461,"status":210,"phases":462,"completion":463,"conditions":464,"interventions":465},"NCT00000441","Drug Therapy for Alcohol Detoxification",[80],"2000-12",[15],[428,466],"carbamazepine",{"trials":468,"activeCount":88},[],{"intervention":410,"totalTrials":107,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":488,"PHASE4":490,"NA":496},{"trials":472,"activeCount":88},[],{"trials":474,"activeCount":88},[],{"trials":476,"activeCount":88},[477],{"nctId":478,"briefTitle":479,"status":210,"phases":480,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":486},"NCT00011765","Effect of Fluoxetine (Prozac) on Domestic Violence",[78],"2007-02-26","2001-02-22",104,[485],"Domestic Violence",[487],"Fluoxetine",{"trials":489,"activeCount":88},[],{"trials":491,"activeCount":88},[492],{"nctId":401,"briefTitle":402,"status":210,"phases":493,"completion":404,"start":405,"enrollment":406,"conditions":494,"interventions":495},[80],[15,18,408],[338,410],{"trials":497,"activeCount":88},[],{"intervention":499,"totalTrials":84,"cells":500},"bupropion",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":520},{"trials":502,"activeCount":88},[],{"trials":504,"activeCount":88},[],{"trials":506,"activeCount":88},[],{"trials":508,"activeCount":88},[],{"trials":510,"activeCount":88},[511],{"nctId":512,"briefTitle":513,"status":210,"phases":514,"primaryCompletion":515,"completion":515,"start":516,"enrollment":386,"conditions":517,"interventions":519},"NCT00044434","Bupropion as a Smoking Cessation Aid in Alcoholics",[80],"2005-04","2002-05",[15,518],"Smoking",[499],{"trials":521,"activeCount":88},[],{"intervention":466,"totalTrials":84,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":538},{"trials":525,"activeCount":88},[],{"trials":527,"activeCount":88},[],{"trials":529,"activeCount":88},[],{"trials":531,"activeCount":88},[],{"trials":533,"activeCount":88},[534],{"nctId":460,"briefTitle":461,"status":210,"phases":535,"completion":463,"conditions":536,"interventions":537},[80],[15],[428,466],{"trials":539,"activeCount":88},[],{"intervention":541,"totalTrials":84,"cells":542},"Methylphenidate",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":562},{"trials":544,"activeCount":88},[],{"trials":546,"activeCount":88},[],{"trials":548,"activeCount":88},[],{"trials":550,"activeCount":88},[],{"trials":552,"activeCount":88},[553],{"nctId":554,"briefTitle":555,"status":210,"phases":556,"completion":557,"start":558,"enrollment":149,"conditions":559,"interventions":561},"NCT00261872","Treatment of Patients With Alcoholism and Attention Deficit Disorder",[80],"2007-04-09","2005-12-01",[15,560],"Attention Deficit Disorder",[541],{"trials":563,"activeCount":88},[],{"intervention":565,"totalTrials":84,"cells":566},"Double Placebo",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":593,"NA":595},{"trials":568,"activeCount":88},[],{"trials":570,"activeCount":88},[],{"trials":572,"activeCount":88},[],{"trials":574,"activeCount":88},[575],{"nctId":576,"briefTitle":577,"status":210,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":583},"NCT00884884","Aripiprazole and Topiramate on Free-Choice Alcohol Use",[78,79],"2015-10","2007-09",90,[18],[565,584,585,586,587,588,589,590,591,592],"Aripiprazole 15, placebo","Aripiprazole 7.5, Placebo","Topiramate 100, Placebo","Topiramate 200, Placebo","Topiramate 100, Aripiprazole 15","Topiramate 100, Aripiprazole 7.5","Topiramate 100, Aripiprazole 15mg","Topiramate 200, Aripiprazole 7.5mg","Topiramate 200, Aripiprazole 15",{"trials":594,"activeCount":88},[],{"trials":596,"activeCount":88},[],{"intervention":584,"totalTrials":84,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":611,"NA":613},{"trials":600,"activeCount":88},[],{"trials":602,"activeCount":88},[],{"trials":604,"activeCount":88},[],{"trials":606,"activeCount":88},[607],{"nctId":576,"briefTitle":577,"status":210,"phases":608,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":609,"interventions":610},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":612,"activeCount":88},[],{"trials":614,"activeCount":88},[],{"intervention":585,"totalTrials":84,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":629,"NA":631},{"trials":618,"activeCount":88},[],{"trials":620,"activeCount":88},[],{"trials":622,"activeCount":88},[],{"trials":624,"activeCount":88},[625],{"nctId":576,"briefTitle":577,"status":210,"phases":626,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":627,"interventions":628},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":630,"activeCount":88},[],{"trials":632,"activeCount":88},[],{"intervention":586,"totalTrials":84,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":647,"NA":649},{"trials":636,"activeCount":88},[],{"trials":638,"activeCount":88},[],{"trials":640,"activeCount":88},[],{"trials":642,"activeCount":88},[643],{"nctId":576,"briefTitle":577,"status":210,"phases":644,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":645,"interventions":646},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":648,"activeCount":88},[],{"trials":650,"activeCount":88},[],{"intervention":587,"totalTrials":84,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":665,"NA":667},{"trials":654,"activeCount":88},[],{"trials":656,"activeCount":88},[],{"trials":658,"activeCount":88},[],{"trials":660,"activeCount":88},[661],{"nctId":576,"briefTitle":577,"status":210,"phases":662,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":663,"interventions":664},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":666,"activeCount":88},[],{"trials":668,"activeCount":88},[],{"intervention":588,"totalTrials":84,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":683,"NA":685},{"trials":672,"activeCount":88},[],{"trials":674,"activeCount":88},[],{"trials":676,"activeCount":88},[],{"trials":678,"activeCount":88},[679],{"nctId":576,"briefTitle":577,"status":210,"phases":680,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":681,"interventions":682},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":684,"activeCount":88},[],{"trials":686,"activeCount":88},[],{"intervention":589,"totalTrials":84,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":701,"NA":703},{"trials":690,"activeCount":88},[],{"trials":692,"activeCount":88},[],{"trials":694,"activeCount":88},[],{"trials":696,"activeCount":88},[697],{"nctId":576,"briefTitle":577,"status":210,"phases":698,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":699,"interventions":700},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":702,"activeCount":88},[],{"trials":704,"activeCount":88},[],{"intervention":590,"totalTrials":84,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":719,"NA":721},{"trials":708,"activeCount":88},[],{"trials":710,"activeCount":88},[],{"trials":712,"activeCount":88},[],{"trials":714,"activeCount":88},[715],{"nctId":576,"briefTitle":577,"status":210,"phases":716,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":717,"interventions":718},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":720,"activeCount":88},[],{"trials":722,"activeCount":88},[],{"intervention":591,"totalTrials":84,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":737,"NA":739},{"trials":726,"activeCount":88},[],{"trials":728,"activeCount":88},[],{"trials":730,"activeCount":88},[],{"trials":732,"activeCount":88},[733],{"nctId":576,"briefTitle":577,"status":210,"phases":734,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":735,"interventions":736},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":738,"activeCount":88},[],{"trials":740,"activeCount":88},[],{"intervention":592,"totalTrials":84,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":755,"NA":757},{"trials":744,"activeCount":88},[],{"trials":746,"activeCount":88},[],{"trials":748,"activeCount":88},[],{"trials":750,"activeCount":88},[751],{"nctId":576,"briefTitle":577,"status":210,"phases":752,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":753,"interventions":754},[78,79],[18],[565,584,585,586,587,588,589,590,591,592],{"trials":756,"activeCount":88},[],{"trials":758,"activeCount":88},[],{"intervention":366,"totalTrials":9,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":762,"activeCount":88},[],{"trials":764,"activeCount":88},[],{"trials":766,"activeCount":88},[767,774,778],{"nctId":768,"briefTitle":769,"status":210,"phases":770,"completion":771,"enrollment":149,"conditions":772,"interventions":773},"NCT00000458","Sertraline and Cognitive Therapy in Depressed Alcoholics",[78],"2002-01",[15,408],[366],{"nctId":359,"briefTitle":360,"status":210,"phases":775,"completion":362,"enrollment":363,"conditions":776,"interventions":777},[78],[15],[338,366],{"nctId":779,"briefTitle":780,"status":210,"phases":781,"completion":463,"conditions":782,"interventions":784},"NCT00000446","Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder",[78],[15,783],"Post-Traumatic Stress Disorder",[366],{"trials":786,"activeCount":88},[],{"trials":788,"activeCount":88},[],{"trials":790,"activeCount":88},[],{"intervention":445,"totalTrials":107,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":794,"activeCount":88},[],{"trials":796,"activeCount":88},[],{"trials":798,"activeCount":88},[799,803],{"nctId":437,"briefTitle":438,"status":210,"phases":800,"completion":440,"start":441,"enrollment":415,"conditions":801,"interventions":802},[78],[443],[445,446],{"nctId":448,"briefTitle":449,"status":210,"phases":804,"completion":451,"enrollment":415,"conditions":805,"interventions":806},[78],[15],[454,428],{"trials":808,"activeCount":88},[],{"trials":810,"activeCount":88},[],{"trials":812,"activeCount":88},[],{"intervention":814,"totalTrials":107,"cells":815},"PF-05190457",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":830,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":817,"activeCount":88},[],{"trials":819,"activeCount":88},[820],{"nctId":821,"briefTitle":822,"status":210,"phases":823,"primaryCompletion":824,"completion":825,"start":826,"enrollment":22,"conditions":827,"interventions":829},"NCT02039349","A Novel Compound for Alcoholism Treatment",[77],"2015-10-01","2017-12-24","2014-01-03",[15,27,18,828,24],"Alcohol Drinking Related Problems",[814],{"trials":831,"activeCount":88},[832],{"nctId":833,"briefTitle":834,"status":190,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT02707055","A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II",[78],"2020-02-20","2020-09-09","2016-06-15",42,[15],[814],{"trials":843,"activeCount":88},[],{"trials":845,"activeCount":88},[],{"trials":847,"activeCount":88},[],{"intervention":376,"totalTrials":107,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":851,"activeCount":88},[],{"trials":853,"activeCount":88},[],{"trials":855,"activeCount":88},[856,860],{"nctId":368,"briefTitle":369,"status":210,"phases":857,"completion":371,"start":372,"enrollment":373,"conditions":858,"interventions":859},[78],[15],[376,338],{"nctId":861,"briefTitle":862,"status":210,"phases":863,"completion":864,"conditions":865,"interventions":866},"NCT00000443","Ondansetron Treatment for Alcoholism",[78],"2000-04",[15],[376],{"trials":868,"activeCount":88},[],{"trials":870,"activeCount":88},[],{"trials":872,"activeCount":88},[],{"intervention":874,"totalTrials":107,"cells":875},"Varenicline",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":901,"PHASE4":903,"NA":905},{"trials":877,"activeCount":88},[],{"trials":879,"activeCount":88},[],{"trials":881,"activeCount":88},[882,891],{"nctId":883,"briefTitle":884,"status":210,"phases":885,"primaryCompletion":886,"completion":887,"start":888,"enrollment":386,"conditions":889,"interventions":890},"NCT01146613","Varenicline for Alcohol Dependence",[78],"2012-06","2012-07","2011-02",[15],[874],{"nctId":892,"briefTitle":893,"status":210,"phases":894,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":900},"NCT03035708","Human Laboratory Study of Varenicline for Alcohol Use Disorder",[77,78],"2018-07-01","2018-07-07","2017-05-01",47,[21],[874],{"trials":902,"activeCount":88},[],{"trials":904,"activeCount":88},[],{"trials":906,"activeCount":88},[],{"intervention":908,"totalTrials":84,"cells":909},"ANS-6637",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":925,"PHASE4":927,"NA":929},{"trials":911,"activeCount":88},[],{"trials":913,"activeCount":88},[],{"trials":915,"activeCount":88},[916],{"nctId":917,"briefTitle":918,"status":190,"phases":919,"primaryCompletion":920,"completion":920,"start":921,"enrollment":922,"conditions":923,"interventions":924},"NCT03970109","HLAB-002 of ANS-6637 for Alcohol Use Disorder",[78],"2020-05-22","2019-10-08",43,[21],[908],{"trials":926,"activeCount":88},[],{"trials":928,"activeCount":88},[],{"trials":930,"activeCount":88},[],{"intervention":932,"totalTrials":84,"cells":933},"Acamprosate",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":953,"PHASE4":955,"NA":957},{"trials":935,"activeCount":88},[],{"trials":937,"activeCount":88},[],{"trials":939,"activeCount":88},[940],{"nctId":941,"briefTitle":942,"status":210,"phases":943,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":949},"NCT00605904","Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics",[78],"2010-09","2011-03","2008-01",37,[15],[932,950,951,952],"Yohimbine","mCPP","Saline",{"trials":954,"activeCount":88},[],{"trials":956,"activeCount":88},[],{"trials":958,"activeCount":88},[],{"intervention":950,"totalTrials":84,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":962,"activeCount":88},[],{"trials":964,"activeCount":88},[],{"trials":966,"activeCount":88},[967],{"nctId":941,"briefTitle":942,"status":210,"phases":968,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":969,"interventions":970},[78],[15],[932,950,951,952],{"trials":972,"activeCount":88},[],{"trials":974,"activeCount":88},[],{"trials":976,"activeCount":88},[],{"intervention":951,"totalTrials":84,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":989,"PHASE4":991,"NA":993},{"trials":980,"activeCount":88},[],{"trials":982,"activeCount":88},[],{"trials":984,"activeCount":88},[985],{"nctId":941,"briefTitle":942,"status":210,"phases":986,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":987,"interventions":988},[78],[15],[932,950,951,952],{"trials":990,"activeCount":88},[],{"trials":992,"activeCount":88},[],{"trials":994,"activeCount":88},[],{"intervention":952,"totalTrials":84,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":998,"activeCount":88},[],{"trials":1000,"activeCount":88},[],{"trials":1002,"activeCount":88},[1003],{"nctId":941,"briefTitle":942,"status":210,"phases":1004,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":1005,"interventions":1006},[78],[15],[932,950,951,952],{"trials":1008,"activeCount":88},[],{"trials":1010,"activeCount":88},[],{"trials":1012,"activeCount":88},[],{"intervention":1014,"totalTrials":84,"cells":1015},"Pioglitazone",{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1017,"activeCount":88},[],{"trials":1019,"activeCount":88},[],{"trials":1021,"activeCount":88},[1022],{"nctId":1023,"briefTitle":1024,"status":190,"phases":1025,"primaryCompletion":1026,"completion":1026,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1031},"NCT01631630","Role of Proinflammatory Signaling in Alcohol Craving",[78],"2015-09","2012-05",16,[18,24,1030,27],"Stress",[1014],{"trials":1033,"activeCount":88},[],{"trials":1035,"activeCount":88},[],{"trials":1037,"activeCount":88},[],{"intervention":1039,"totalTrials":84,"cells":1040},"Pexacerfont",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1042,"activeCount":88},[],{"trials":1044,"activeCount":88},[],{"trials":1046,"activeCount":88},[1047],{"nctId":1048,"briefTitle":1049,"status":210,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":350,"conditions":1053,"interventions":1055},"NCT01227980","Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^",[78],"2014-07","2010-10",[27,18,15,1054],"Anxiety Disorder",[1039],{"trials":1057,"activeCount":88},[],{"trials":1059,"activeCount":88},[],{"trials":1061,"activeCount":88},[],{"intervention":1063,"totalTrials":84,"cells":1064},"Quetiapine fumarate",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1066,"activeCount":88},[],{"trials":1068,"activeCount":88},[],{"trials":1070,"activeCount":88},[1071],{"nctId":1072,"briefTitle":1073,"status":210,"phases":1074,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1080},"NCT00498628","Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency",[78],"2009-08","2010-03","2007-12",224,[15,35],[1063],{"trials":1082,"activeCount":88},[],{"trials":1084,"activeCount":88},[],{"trials":1086,"activeCount":88},[],{"intervention":1088,"totalTrials":84,"cells":1089},"sodium valproate",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1091,"activeCount":88},[],{"trials":1093,"activeCount":88},[],{"trials":1095,"activeCount":88},[1096],{"nctId":1097,"briefTitle":1098,"status":210,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1105},"NCT00000439","Drug Treatment for Alcoholics With Bipolar Disorder",[78],"2003-08","2000-10",72,[15,1104],"Bipolar Disorder",[1088],{"trials":1107,"activeCount":88},[],{"trials":1109,"activeCount":88},[],{"trials":1111,"activeCount":88},[],{"intervention":1113,"totalTrials":84,"cells":1114},"Aprepitant",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1116,"activeCount":88},[],{"trials":1118,"activeCount":88},[],{"trials":1120,"activeCount":88},[1121],{"nctId":1122,"briefTitle":1123,"status":210,"phases":1124,"primaryCompletion":1125,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1131},"NCT00896038","The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD",[78],"2014-05","2014-08","2009-05",58,[15,18,1130],"Posttraumatic Stress Disorder",[1113],{"trials":1133,"activeCount":88},[],{"trials":1135,"activeCount":88},[],{"trials":1137,"activeCount":88},[],{"intervention":258,"totalTrials":84,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1141,"activeCount":88},[],{"trials":1143,"activeCount":88},[],{"trials":1145,"activeCount":88},[1146],{"nctId":250,"briefTitle":251,"status":210,"phases":1147,"primaryCompletion":253,"completion":253,"start":254,"enrollment":8,"conditions":1148,"interventions":1149},[78],[256,24,15],[258,51],{"trials":1151,"activeCount":88},[],{"trials":1153,"activeCount":88},[],{"trials":1155,"activeCount":88},[],{"intervention":1157,"totalTrials":84,"cells":1158},"gabapentin enacarbil",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1160,"activeCount":88},[],{"trials":1162,"activeCount":88},[],{"trials":1164,"activeCount":88},[1165],{"nctId":1166,"briefTitle":1167,"status":210,"phases":1168,"primaryCompletion":1169,"completion":1169,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1173},"NCT02252536","HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder",[78],"2017-03","2015-06",346,[21],[1157],{"trials":1175,"activeCount":88},[],{"trials":1177,"activeCount":88},[],{"trials":1179,"activeCount":88},[],{"intervention":1181,"totalTrials":84,"cells":1182},"Baclofen",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1197,"PHASE4":1199,"NA":1201},{"trials":1184,"activeCount":88},[],{"trials":1186,"activeCount":88},[],{"trials":1188,"activeCount":88},[1189],{"nctId":1190,"briefTitle":1191,"status":210,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":16,"conditions":1195,"interventions":1196},"NCT01751386","Baclofen for Treating Anxiety and Alcoholism",[78],"2016-08-17","2012-12-03",[15,18,828,24,1054],[1181],{"trials":1198,"activeCount":88},[],{"trials":1200,"activeCount":88},[],{"trials":1202,"activeCount":88},[],{"intervention":1204,"totalTrials":84,"cells":1205},"LY686017",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1207,"activeCount":88},[],{"trials":1209,"activeCount":88},[],{"trials":1211,"activeCount":88},[1212],{"nctId":1213,"briefTitle":1214,"status":210,"phases":1215,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT00310427","Effect of LY686017 on Alcohol Craving",[78],"2008-03","2006-03",66,[18,15],[1204],{"trials":1222,"activeCount":88},[],{"trials":1224,"activeCount":88},[],{"trials":1226,"activeCount":88},[],{"intervention":1228,"totalTrials":84,"cells":1229},"Memantine",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1231,"activeCount":88},[],{"trials":1233,"activeCount":88},[],{"trials":1235,"activeCount":88},[1236],{"nctId":1237,"briefTitle":1238,"status":210,"phases":1239,"primaryCompletion":451,"completion":451,"start":1240,"enrollment":581,"conditions":1241,"interventions":1243},"NCT00246415","A Placebo-Controlled Trial of Memantine for Alcohol Dependence",[78],"2002-11",[1242,35],"Alcohol Dependence (Primary Condition)",[1228],{"trials":1245,"activeCount":88},[],{"trials":1247,"activeCount":88},[],{"trials":1249,"activeCount":88},[],{"intervention":1251,"totalTrials":84,"cells":1252},"Instranasal Oxytocin",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1254,"activeCount":88},[],{"trials":1256,"activeCount":88},[],{"trials":1258,"activeCount":88},[1259],{"nctId":1260,"briefTitle":1261,"status":210,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":149,"conditions":1265,"interventions":1266},"NCT03878316","Intranasal Oxytocin for the Treatment of Alcohol Use Disorder",[78],"2023-10-13","2022-06-29",[21,151],[1251],{"trials":1268,"activeCount":88},[],{"trials":1270,"activeCount":88},[],{"trials":1272,"activeCount":88},[],{"intervention":1274,"totalTrials":84,"cells":1275},"Morphine",{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1277,"activeCount":88},[],{"trials":1279,"activeCount":88},[],{"trials":1281,"activeCount":88},[1282],{"nctId":1283,"briefTitle":1284,"status":210,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1288,"conditions":1289,"interventions":1293},"NCT01878006","Genetic Effects on Dopamine Response to an Opiate",[78],"2017-04-27","2013-06-13",15,[1290,1291,1292],"Polymorphism-Genetic","Pain","Addiction",[1274],{"trials":1295,"activeCount":88},[],{"trials":1297,"activeCount":88},[],{"trials":1299,"activeCount":88},[],{"intervention":1301,"totalTrials":84,"cells":1302},"Levetiracetam XR",{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1304,"activeCount":88},[],{"trials":1306,"activeCount":88},[],{"trials":1308,"activeCount":88},[1309],{"nctId":1310,"briefTitle":1311,"status":210,"phases":1312,"primaryCompletion":1313,"completion":1052,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1317},"NCT00970814","Levetiracetam XR in Very Heavy Drinkers",[78],"2010-08","2009-10",130,[15],[1301,1318],"Sugar Pill",{"trials":1320,"activeCount":88},[],{"trials":1322,"activeCount":88},[],{"trials":1324,"activeCount":88},[],{"intervention":1318,"totalTrials":84,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1328,"activeCount":88},[],{"trials":1330,"activeCount":88},[],{"trials":1332,"activeCount":88},[1333],{"nctId":1310,"briefTitle":1311,"status":210,"phases":1334,"primaryCompletion":1313,"completion":1052,"start":1314,"enrollment":1315,"conditions":1335,"interventions":1336},[78],[15],[1301,1318],{"trials":1338,"activeCount":88},[],{"trials":1340,"activeCount":88},[],{"trials":1342,"activeCount":88},[],{"intervention":1344,"totalTrials":84,"cells":1345},"GSK561679",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1347,"activeCount":88},[],{"trials":1349,"activeCount":88},[],{"trials":1351,"activeCount":88},[1352],{"nctId":1353,"briefTitle":1354,"status":210,"phases":1355,"primaryCompletion":1026,"completion":1026,"start":1356,"enrollment":1357,"conditions":1358,"interventions":1359},"NCT01187511","CRF1 Antagonist GSK561679 in Alcoholism",[78],"2010-01",44,[18],[1344],{"trials":1361,"activeCount":88},[],{"trials":1363,"activeCount":88},[],{"trials":1365,"activeCount":88},[],{"intervention":1367,"totalTrials":84,"cells":1368},"ABT-436",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1370,"activeCount":88},[],{"trials":1372,"activeCount":88},[],{"trials":1374,"activeCount":88},[1375],{"nctId":1376,"briefTitle":1377,"status":210,"phases":1378,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":1383,"interventions":1385},"NCT01613014","ABT-436 for Alcohol Dependence",[78],"2015-05","2015-07","2013-02",150,[18,35,1384,15],"Alcohol Use Disorders",[1367,1386],"Matched Placebo - Sugar Pill",{"trials":1388,"activeCount":88},[],{"trials":1390,"activeCount":88},[],{"trials":1392,"activeCount":88},[],{"intervention":1386,"totalTrials":84,"cells":1394},{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1405,"PHASE4":1407,"NA":1409},{"trials":1396,"activeCount":88},[],{"trials":1398,"activeCount":88},[],{"trials":1400,"activeCount":88},[1401],{"nctId":1376,"briefTitle":1377,"status":210,"phases":1402,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":1403,"interventions":1404},[78],[18,35,1384,15],[1367,1386],{"trials":1406,"activeCount":88},[],{"trials":1408,"activeCount":88},[],{"trials":1410,"activeCount":88},[],{"intervention":1412,"totalTrials":84,"cells":1413},"SR141716",{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1415,"activeCount":88},[],{"trials":1417,"activeCount":88},[],{"trials":1419,"activeCount":88},[1420],{"nctId":1421,"briefTitle":1422,"status":210,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1428},"NCT00075205","Rimonabant to Reduce Alcohol Consumption",[78],"2007-03-15","2003-12-31",54,[30,24],[1412],{"trials":1430,"activeCount":88},[],{"trials":1432,"activeCount":88},[],{"trials":1434,"activeCount":88},[],{"intervention":1436,"totalTrials":84,"cells":1437},"ASP8062",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1439,"activeCount":88},[],{"trials":1441,"activeCount":88},[],{"trials":1443,"activeCount":88},[1444],{"nctId":1445,"briefTitle":1446,"status":210,"phases":1447,"primaryCompletion":1448,"completion":1448,"start":1449,"enrollment":1450,"conditions":1451,"interventions":1452},"NCT05096117","Human Laboratory Study of ASP8062 for Alcohol Use Disorder",[78],"2023-03-22","2021-12-13",60,[21,24,118],[1436],{"trials":1454,"activeCount":88},[],{"trials":1456,"activeCount":88},[],{"trials":1458,"activeCount":88},[],{"intervention":1460,"totalTrials":84,"cells":1461},"Nalmefene",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1476,"PHASE3":1478,"PHASE4":1480,"NA":1482},{"trials":1463,"activeCount":88},[],{"trials":1465,"activeCount":88},[1466],{"nctId":1467,"briefTitle":1468,"status":210,"phases":1469,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1475},"NCT02639273","Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation",[77],"2023-12-08","2016-06-08",13,[1474],"AUD",[1460],{"trials":1477,"activeCount":88},[],{"trials":1479,"activeCount":88},[],{"trials":1481,"activeCount":88},[],{"trials":1483,"activeCount":88},[],{"intervention":1485,"totalTrials":84,"cells":1486},"Oxytocin",{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1500,"PHASE3":1502,"PHASE4":1504,"NA":1506},{"trials":1488,"activeCount":88},[],{"trials":1490,"activeCount":88},[1491],{"nctId":1492,"briefTitle":1493,"status":1494,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":88,"conditions":1498,"interventions":1499},"NCT02711189","Oxytocin in Alcohol Use Disorder","WITHDRAWN",[77],"2019-02-22","2016-03-08",[15],[1485],{"trials":1501,"activeCount":88},[],{"trials":1503,"activeCount":88},[],{"trials":1505,"activeCount":88},[],{"trials":1507,"activeCount":88},[],{"intervention":1509,"totalTrials":84,"cells":1510},"Docosahexaenoic acid",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1525,"PHASE3":1527,"PHASE4":1529,"NA":1531},{"trials":1512,"activeCount":88},[],{"trials":1514,"activeCount":88},[1515],{"nctId":1516,"briefTitle":1517,"status":210,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":1521,"conditions":1522,"interventions":1523},"NCT00014027","Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress",[77],"2008-04-11","2001-04-04",97,[30],[1509,1524],"Eicosapentaenoic acid",{"trials":1526,"activeCount":88},[],{"trials":1528,"activeCount":88},[],{"trials":1530,"activeCount":88},[],{"trials":1532,"activeCount":88},[],{"intervention":1524,"totalTrials":84,"cells":1534},{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1536,"activeCount":88},[],{"trials":1538,"activeCount":88},[1539],{"nctId":1516,"briefTitle":1517,"status":210,"phases":1540,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":1521,"conditions":1541,"interventions":1542},[77],[30],[1509,1524],{"trials":1544,"activeCount":88},[],{"trials":1546,"activeCount":88},[],{"trials":1548,"activeCount":88},[],{"trials":1550,"activeCount":88},[],{"intervention":1552,"totalTrials":84,"cells":1553},"Methylphenidate Pill",{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1570,"PHASE3":1572,"PHASE4":1574,"NA":1576},{"trials":1555,"activeCount":88},[],{"trials":1557,"activeCount":88},[1558],{"nctId":1559,"briefTitle":1560,"status":210,"phases":1561,"primaryCompletion":1449,"completion":1562,"start":1563,"enrollment":1564,"conditions":1565,"interventions":1566},"NCT03326245","Dopaminergic Modulation of Brain Activation Using Simultaneous PET\u002FPharmacological MRI",[77],"2024-02-08","2018-01-29",25,[32],[1552,1567,1568,1569],"Oral Placebo","Intravenous Placebo","Intravenous methylphenidate",{"trials":1571,"activeCount":88},[],{"trials":1573,"activeCount":88},[],{"trials":1575,"activeCount":88},[],{"trials":1577,"activeCount":88},[],{"intervention":1567,"totalTrials":84,"cells":1579},{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1588,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1581,"activeCount":88},[],{"trials":1583,"activeCount":88},[1584],{"nctId":1559,"briefTitle":1560,"status":210,"phases":1585,"primaryCompletion":1449,"completion":1562,"start":1563,"enrollment":1564,"conditions":1586,"interventions":1587},[77],[32],[1552,1567,1568,1569],{"trials":1589,"activeCount":88},[],{"trials":1591,"activeCount":88},[],{"trials":1593,"activeCount":88},[],{"trials":1595,"activeCount":88},[],{"intervention":1568,"totalTrials":84,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1606,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":88},[],{"trials":1601,"activeCount":88},[1602],{"nctId":1559,"briefTitle":1560,"status":210,"phases":1603,"primaryCompletion":1449,"completion":1562,"start":1563,"enrollment":1564,"conditions":1604,"interventions":1605},[77],[32],[1552,1567,1568,1569],{"trials":1607,"activeCount":88},[],{"trials":1609,"activeCount":88},[],{"trials":1611,"activeCount":88},[],{"trials":1613,"activeCount":88},[],{"intervention":1569,"totalTrials":84,"cells":1615},{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1617,"activeCount":88},[],{"trials":1619,"activeCount":88},[1620],{"nctId":1559,"briefTitle":1560,"status":210,"phases":1621,"primaryCompletion":1449,"completion":1562,"start":1563,"enrollment":1564,"conditions":1622,"interventions":1623},[77],[32],[1552,1567,1568,1569],{"trials":1625,"activeCount":88},[],{"trials":1627,"activeCount":88},[],{"trials":1629,"activeCount":88},[],{"trials":1631,"activeCount":88},[],{"intervention":279,"totalTrials":84,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1640,"PHASE2":1642,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1635,"activeCount":88},[1636],{"nctId":270,"briefTitle":271,"status":210,"phases":1637,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":1638,"interventions":1639},[76],[32,277],[279,120,121],{"trials":1641,"activeCount":88},[],{"trials":1643,"activeCount":88},[],{"trials":1645,"activeCount":88},[],{"trials":1647,"activeCount":88},[],{"trials":1649,"activeCount":88},[],{"intervention":1651,"totalTrials":84,"cells":1652},"neuroinflammation",{"EARLY_PHASE1":1653,"PHASE1":1664,"PHASE2":1666,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1654,"activeCount":88},[1655],{"nctId":1656,"briefTitle":1657,"status":210,"phases":1658,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1663},"NCT02233868","Brain Inflammation and Function in Alcoholism",[76],"2021-08-16","2015-02-19",74,[118],[1651],{"trials":1665,"activeCount":88},[],{"trials":1667,"activeCount":88},[],{"trials":1669,"activeCount":88},[],{"trials":1671,"activeCount":88},[],{"trials":1673,"activeCount":88},[],{"intervention":1675,"totalTrials":84,"cells":1676},"Brain Dopamine Reactivity",{"EARLY_PHASE1":1677,"PHASE1":1687,"PHASE2":1689,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1678,"activeCount":88},[1679],{"nctId":1680,"briefTitle":1681,"status":1494,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":1683,"enrollment":88,"conditions":1684,"interventions":1686},"NCT02233829","Dopamine Rhythms in Health and Addiction",[76],"2024-04-23",[1685],"Cocaine Abuse",[1675],{"trials":1688,"activeCount":88},[],{"trials":1690,"activeCount":88},[],{"trials":1692,"activeCount":88},[],{"trials":1694,"activeCount":88},[],{"trials":1696,"activeCount":88},[],{"intervention":1698,"totalTrials":84,"cells":1699},"F-18FDG",{"EARLY_PHASE1":1700,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1701,"activeCount":88},[1702],{"nctId":1703,"briefTitle":1704,"status":210,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1709,"interventions":1710},"NCT02193425","Reliability of the Human Brain Connectome",[76],"2023-05-23","2015-06-08",112,[32],[1698],{"trials":1712,"activeCount":88},[],{"trials":1714,"activeCount":88},[],{"trials":1716,"activeCount":88},[],{"trials":1718,"activeCount":88},[],{"trials":1720,"activeCount":88},[],{"intervention":1722,"totalTrials":84,"cells":1723},"FCWAY",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1725,"activeCount":88},[],{"trials":1727,"activeCount":88},[],{"trials":1729,"activeCount":88},[],{"trials":1731,"activeCount":88},[],{"trials":1733,"activeCount":88},[],{"trials":1735,"activeCount":88},[1736],{"nctId":1737,"briefTitle":1738,"status":210,"phases":1739,"completion":440,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1743},"NCT00011752","Serotonin in Alcoholism",[],"2001-02",75,[15,30],[1722]]